January 24, 2021

The Niche

Trusted stem cell blog & resources

Search Results for: amniotic

8 min read

Some readers suggested earlier this year that I look into a clinic firm called ‘Stem Cell Centers’ with its owner Travis Autor. I didn’t have time to do much since I’ve been very busy in the lab before the state Attorney Generals of Iowa and Nebraska sued them based on a number of allegations including in the Iowa case for fraud. This is a very significant development for the field. The suits focus both on medically unproven and non-FDA approved stem cells and exosomes. …Read More

10 min read

One of the most common questions that patients have asked me over the last decade is, “how much do stem cells cost?” They actually seem most often to want to know more specifically how much the treatments should cost. To try to authoritatively answer this we need data from the present and past along with expert perspectives. These kinds of questions on what are common and reasonable prices have continued in 2021. However, the types of queries have also evolved as things have gotten …Read More

5 min read

The FDA has stem cell clinics squarely on its radar screen now and it’s pulling the trigger with many letters going out to this problematic industry. In the past, sometimes years went by with no letters at all or one letter in total to stem cell clinics so this marks a major shift. Background on lead-up to wave of FDA activity I count 7 letters in a less than two-month span from mid-March to now, which may be the most in history in the …Read More

4 min read

When the number of stem cell clinical studies and trials listed for COVID-19 first started spiraling upward it seemed likely that stem cell clinics and other firms in that arena would get interested. I thought that we’d see the unproven regenerative medicine coronavirus bandwagon quickly grow. Unfortunately, there are reasons to be increasingly concerned here. For instance, the idea that stem cells or exosomes could successfully treat COVID-19 is getting more buzz by clinics and other related firms. Sometimes it is getting hyped too in the …Read More

3 min read

Should we call it stem cell synchronicity for stem cell supplier firm Invitrx? What was it about March 16? Sometimes strange things happen in the stem cell world such as last week on March 16 I wrote that the FDA needs to do more about unproven exosomes, and then on the same day a new FDA warning letter went out to Invitrx mentioning almost as an aside an unapproved exosome product amongst many other products and issues. No, I don’t have some secret red telephone where I …Read More

6 min read

People ask me questions about stem cells all the time so I decide to do a new blog series answering your questions. Today’s post is  the first in this new stem cell Q&A series. Past series have included my Elephant in the Lab series that provides some insights into the craziness that sometimes goes on in academic research with sometimes biting science humor. I’ve also gotten many great questions on my Reddit AMAs both about stem cells and CRISPR. I’m focusing today on a …Read More

5 min read

Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for 2019. What grade will I get for 2020? I don’t yet of course, but I often can’t resist making positive predictions even if they are relatively high risk in …Read More

6 min read

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do? Below I grade my 20 predictions for this year. You can in addition see my grading of my 2018 predictions here. In the next week or so I’ll also …Read More

4 min read

The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to Liveyon, R3 Stem Cell, Stemell, and others. RAPS has more on the story of the new letter here. This newest untitled letter went to RichSource Stem Cells, Inc. and its CEO Sara Oracle, a firm which markets an unusual “combo” product described this way by the FDA, “a combination …Read More

3 min read

After almost a decade blogging about stem cells from just about every angle, it’s interesting to consider trends in the types of questions I get asked such as this much more common one now as compared to 2010: How much is stem cell therapy? What does a patient pay on average for stem cells in 2019? How much does insurance cover? Cost is on people’s minds. In a way that’s not so surprising for a few reasons. First, as compared to many years back, …Read More